Skyhawk SKY-0515 Huntington's Trial Results
Analysis based on 8 articles · First reported Jun 30, 2026 · Last updated Jun 30, 2026
The positive 12-month interim data for SKY-0515 in Huntington s disease is expected to significantly boost investor confidence in Skyhawk Therapeutics, potentially leading to increased valuation and future investment in the biotechnology sector. The lack of approved disease-modifying treatments for Huntington s disease makes this development particularly impactful, suggesting a potential breakthrough that could open up a new market for effective therapies.
Skyhawk Therapeutics announced positive 12-month interim results from its Phase 1/2 clinical trial of SKY-0515, an oral investigational treatment for Huntington s disease. The data showed favorable and consistent trends across all cUHDRS subcomponents, including Total Functional Capacity, Total Motor Score, Symbol Digit Modalities Test, and Stroop Word Reading Test. Participants receiving SKY-0515 demonstrated improvements or stabilization compared to expected worsening based on natural history datasets. Additionally, the treatment led to dose-dependent reductions in mutant huntingtin protein and PMS1 mRNA, key biomarkers for disease progression. Clinician and Patient Global Impression surveys also indicated improvement or stabilization of the disease. SKY-0515 has shown good safety and tolerability, with over 175 participants enrolled across five countries. Skyhawk Therapeutics is also advancing its Phase 2/3 FALCON-HD pivotal program, with enrollment complete in Australia and New Zealand, and active treatment ongoing in other sites worldwide.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard